Product
Mesalazine
8 clinical trials
14 indications
Indication
ColitisIndication
UlcerativeIndication
Inflammatory Bowel DiseaseIndication
ulcerative colitisIndication
efficacyIndication
SelfIndication
BiologicsIndication
MesalazineIndication
Para-aminosalicylic acidIndication
Ulcerative Colitis ExacerbationIndication
Protozoan InfectionsIndication
HelminthiasisIndication
Crohn's diseaseIndication
Oral UlcerClinical trial
A Randomised, Double-blind, Double-dummy, Multicentre, Phase III, Non Inferiority Trial of an Oral Mesalazine Formulation in Patients With Active Mild to Moderate Ulcerative Colitis for the Induction of Remission.Status: Not yet recruiting, Estimated PCD: 2025-08-01
Clinical trial
Clinical Study to Evaluate the Possible Efficacy and Safety of Minocycline in Patients With Ulcerative Colitis Treated With MesalamineStatus: Recruiting, Estimated PCD: 2027-01-20
Clinical trial
A Randomized Controlled Study of Qinghua Quyu Prescription Rectal Instillation for the Treatment of Ulcerative ColitisStatus: Recruiting, Estimated PCD: 2025-12-31
Clinical trial
Adherence of a 1.600 mg Single Tablet 5-ASA Treatment of Ulcerative Colitis (EASI-trial)Status: Recruiting, Estimated PCD: 2024-12-31
Clinical trial
Efficacy of Mesalazine Combined With Biologics in the Treatment of Moderate to Severe Ulcerative Colitis: a Multicenter, Prospective, Randomized, Controlled Clinical StudyStatus: Recruiting, Estimated PCD: 2024-01-15
Clinical trial
Oral 5-aminosalicylic Acid Withdrawal in Long Standing Inactive Ulcerative Colitis: A Double-blind, Randomized, Placebo-controlled TrialStatus: Completed, Estimated PCD: 2021-09-10
Clinical trial
Role of Intestinal Protozoa and Helminths in the Course of Ulcerative ColitisStatus: Active (not recruiting), Estimated PCD: 2025-07-01
Clinical trial
The Efficacy of Topically Applied Mesalazine Sustained-Release Tablets in Oral Lesions of Crohn's DiseaseStatus: Withdrawn, Estimated PCD: 2016-12-01